Title : Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia.

Pub. Date : 2011 May

PMID : 21213107






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 As the genetically polymorphic cytochrome P450 (CYP), enzyme CYP2C9 is mainly responsible for the hepatic metabolism of sulfonylureas (SUs), we hypothesized that the slow-metabolizer genotypes *2/*2, *2/*3, and *3/*3 might be overrepresented in type 2 diabetic patients with SH. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens
2 As the genetically polymorphic cytochrome P450 (CYP), enzyme CYP2C9 is mainly responsible for the hepatic metabolism of sulfonylureas (SUs), we hypothesized that the slow-metabolizer genotypes *2/*2, *2/*3, and *3/*3 might be overrepresented in type 2 diabetic patients with SH. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens
3 However, in the control group, patients with CYP2C9 genotypes, predicting slower metabolism of SU drugs, were treated with significantly lower doses (p = 0.027) than were extensive metabolizers, whereas in the patient group with severe hypoglycemia, the dose was the same for all genotype groups. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens